Emerging concepts in drug discovery for cancer therapy
Open Access
- 2 November 2022
- journal article
- editorial
- Published by Wiley in Molecular Oncology
- Vol. 16 (21) , 3757-3760
Abstract
No abstract availableFunding Information
- Fundación Científica Asociación Española Contra el Cáncer
- Cancerfonden (180640)
- Vetenskapsrådet (538‐2014‐31)
This publication has 24 references indexed in Scilit:
- Senescent intimal foam cells are deleterious at all stages of atherosclerosisScience, 2016
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer modelsNature, 2016
- Naturally occurring p16Ink4a-positive cells shorten healthy lifespanNature, 2016
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- Clearance of p16Ink4a-positive senescent cells delays ageing-associated disordersNature, 2011
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutationsNature Structural & Molecular Biology, 2011
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradationProceedings of the National Academy of Sciences, 2001
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948